Pharmacogenetics in biological perspective

Pharmacological Reviews

Volumn 49, Issue 4, 1997, Pages 369-379

  Kalow, W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TOXIC SUBSTANCE;

ARTHROPOD; BACTERIUM; EVOLUTION; GENETIC RESISTANCE; GENETIC VARIABILITY; HUMAN; INBORN ERROR OF METABOLISM; INTOXICATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TOXICOKINETICS; XENOBIOTIC METABOLISM;

ANIMALS; ARTHROPODS; BACTERIA; CYTOCHROME P-450 CYP2D6; DRUG RESISTANCE; EVOLUTION; GENE FREQUENCY; HUMANS; PHARMACOGENETICS; PHARMACOKINETICS; VARIATION (GENETICS); XENOBIOTICS;

EID: 0031461131     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. AKLILLU, E., PERSSON, I., BERTILSSON, L., JOHANSHON, I., RODRIGUES, F., AND INGELMAN-SUNDBERG, M.: Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated und multi-duplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278: 441-446, 1996.
2. BALANT, L. P., BALANT-GORGIA, A. E., GEX-FABRY, M., AND EICHELBAUM, M.: Genetic polymorphisms in human drug metabolism. In New Trends in Pharmacokinetics, ed. by A. Rescigno and A. K. Thakur, pp. 391-410, Plenum Press, New York, 1991.
3. BENITEZ, J., LLERENA, A., AND COBALEDA, J.: Debrisoquin oxidation polymorphism in a Spanish population. Clin. Pharmacol, Ther. 44: 74-77, 1988.
4. BENNETT, P. M.: The spread of drug resistance. In Population Genetics of Bacteria, ed. by S. Baumberg, J. P. W. Young, E. M. H. Wellington, and J. R. Saunders, pp. 317-344, Cambridge University Press, Cambridge, UK, 1995.
5. BEHTILSSON, L., ALM, C., DE LAS CARRERAS, C., WIDEN, J., EDMAN, G., AND SCHALLlNG, D.: Debrisoquine hydroxylatjon polymorphism and personality. Lancet 1: 555, 1989 (letter).
6. BETTMANN, O. L.: A Pictorial History of Medicine, Charles C. Thomas, Springfield. IL, 1956.
7. BEUTLER, E.: Study of glucuse-6-phosphate dehydrogenase: history and molecular biology. Am. J. Hematol. 42: 53-58, 1993.
8. BHATNAGAR, D., LILLEHOJ, E. B., AND ARORA, D. K.: Handbook of Applied Mycology: Mycotoxins in Ecological Systems, Marcel Dekker, Inc., New York, NY, 1992.
9. BROWN, A. W. A.: Insecticide Resistance in Arthropods, World Health Organization, Geneva, Switzerland, 1958.
10. BROWN, A. W. A.: Pest Resistance to Pesticides. In Pesticides in the Environment, ed. by R. White-Stevens, pp. 457-652. Marcel Dekker. Inc., New York, 1971.
11. BRUNHAM, R. C., PLUMMER, F. A., AND STEPHENS, R. S.: Bacterial antigenic variation, host immune response, and pathogen-host convolution. Infect. Immun. 61: 2273-2276, 1993.
12. BRYAN, L. E.: Bacterial resistance and susceptibility to chemotherapeutic agents. Cambridge University Press, Cambridge. UK, 1995.
13. CAVALLI-SFORZA, L. L., AND BUDMER, W. F.: The Genetics of Human Populations, Freeman & Co., San Francisco, CA, 1971.
14. CHILDS, R.: A logic of disease. In The Metabolic und Molecular Bases of Inherited Disease, ed. by C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, pp. 229-257, McGraw-Hill, Inc., New York, 1990.
15. CLARK, A. J.: General Pharmacology (Handbook of Experimental Pharmacology Series), vol. 4, Springer-Verlag, Berlin, 1937.
16. CONNEY, A. H.: Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19: 317-366, 1967.
17. COOPER, D. N., KRAWCZAK, M., AND ANTONARAKIS, S. E.: The nature and mechanisms of human gene mutation. In The Metabolic and Molecular Bases of Inherited Disease, ed. by C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, pp, 259-291. McGraw-Hill, Inc., New York, 1995.
18. DAHL, M. L., JOHANSSON, I., BERTILSSON, L., INGELMAN-SUNDBERG, M., AND SJOQVIST, F.: Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274: 516-520, 1995.
19. DALY, A. K., CHOLERTON, S., GREGORY, W., AND IDLE, J. R.: Metabolic polymorphisms. Pharmacol. Ther. 57: 129-160, 1993.
20. DEAN, M., CARRINGTON, M., WINKLER, C., HUTTLEY, G. A., SMITH, M. W., ALLIKMETS, R., GOEDERT, J. J., BUCHBINDER, S. P., VITTINGHOFF, E., GOMPERTS, E., DONFIELD, S., VLAHOV, D., KASLOW, R., SAAH, A., RlNALDO, C., DETELS. R., AND O'BRIEN, S. J.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science (Wash. DC) 273: 1856-1862, 1996.
21. EICHELBAUM, M., AND GROSS, A. S.: The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. In Pharmacogenetics of Drug Metabolism (International Encyclopedia of Pharmacology & Therapeutics Series), ed. by W. Kalow, vol. 137, pp. 625-648, Pergamon Press, New York, 1992.
22. ENDRENYI, L., AND PATEL, M.: Evaluation of two assumptions: single straight line, and single normal distribution. Trends Pharmacol. Sci. 12: 293-296. 1991.
23. FORD, E. B.: Polymorphism and taxonomy. In The New Systematics, ed. by J. Huxley, pp. 493-573, Clarendon Press, Oxford, 1940.
24. FORD, M. D., HOLLOMAN, D. W., KHAMBAY, B. P. S., AND SAWICKI, R. M.: Combating Resistance to Xenobiotics, Ellis Horwood, Chichester, 1967.
25. FORRESTER, N. W., CAHILL, M., BIRD, L. J., AND LAYLAND, J. K.: Management of pyrethroid and endosulfan resistance in Helicoverpa armigera (Lopidoptera: Noctuidae) in Australia. Bull. Entomol. Res. 1(suppl): 1-132, 1993.
26. GABRIEL, S. E., BRIGMAN, K. N., KOLLER, B. H., BOUCHER, R. C., AND STRUTTS, M. J.: Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science (Wash. DC) 266: 107-109, 1994.
27. GEORGHIOU, G. P., AND SAITO, T.: Pest Resistance to Pesticides, Plenum Press, New York, 1983.
28. GONZALEZ, F. J., AND NEBERT, D. W.: Evolution of the P450 gene superfamily: animal-plant 'warfare,' molecular drive and human genetic differences in drug oxidation. Trends Genet. 6: 182-186, 1990.
29. GRAHAM-BRYCE, I. J.: Resistance to pesticides and antibiotics: how far is it comprehensible and manageable? In Combating Resistance to Xenobiotics, ed. by M. G. Ford, D. W. Holloman, B. P. S. Khambay, and R. M. Sawicki, pp. 11-25, Ellis Horwood, Chichester, 1987.
30. GUENGERICH, F. P., KlM, D. H.: In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis (Oxf) 11: 2275-2279, 1990.
31. HALDANE, J. B. S,: Disease and Evolution. La Ricerca Sci 19: 68-75, 1949.
32. HELLRIEFEL, E. T., BJORNSSON. T. D., AND HAUCK, W. W.: Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 60: 601-607, 1996.
33. HILL, A. V. S., ALLSOPP, C. E. M., KWIATKOWSKI, D., ANSTEY, N. M., TWUMASI, P., ROWE, P. A., BENNETT, S., BHEWSTER, D., MCMICHAEL, A. J., AND GREENWOOD, B. M.: Common West African HLA antigens are associated with protection from severe malaria. Nature (Lond.) 352: 595-600, 1991.
34. HUANG, Y., PAXTON, W. A., WOLINSKY, S. M., NEUMANN, A. U., ZHANG, L., HE, T., KANG, S., CERADINI, D., JIN, Z., YAZDANBAKHSH. K., KUNSTMAN, K., ERICKSON, D., DRAGON, E., LANDAU, N. R., PHAIR, J., HO, D. D., AND KOUP, R. A.: The role of a mutant CCRS allele in HIV-1 transmission and disease progression. Nat. Med. 2: 1240-1243, 1996.
35. JELINEK, C. F., POHLAND, A. E., WOOD, G. E.: Worldwide occurrence of mycotoxins in foods and feeds: an update. J. Assoc. Off. Anal. Chem. 78: 223-230 1989.
36. JOHANSSON, I., YUE, Q. Y., DAHL, M. L., HEIM, M., SAWE, J., BERTILSSON, L., MEYER, U. A., SJÖQVIST, F., AND INOELMAN-SUNDBERG, M.: Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur. J. Clin. Pharmacol. 40: 553-556, 1991.
37. KALOW, W.: Continuous versus polymorphic variation: practical aspects. In Pharmacogenetics: Bridging the Gap Between Basic Science and Clinical Application, ed. by J. Schlegel and W. Hori, pp. 4.2.1-4.2.18, IBC Biomedical Library Series, Southborough, MA, 1996.
38. KALOW, W.: Interethnic variation of drug metabolism. Trends Pharmacol. Sci. 12: 102-107, 1991.
39. KALOW, W.: Letalitätsbestimmungen und Variation. Naunyn-Schmiedeberga Arch. Pharmacol. 207: 301-323, 1949.
40. KALOW, W.: Pharmacoanthropology and the genetics of drug metabolism. In Pharmacogenetics of Drug Metabolism (International Encyclopedia of Pharmacology & Therapeutics Series), ed. by W. Kalow, vol. 137, pp. 865-877. Porgamon Press, Inc., New York, 1992a.
41. KALOW, W.: Pharmacogenetics of Drug Metabolism (International Encyclopedia of Pharmacology & Therapeutics Series), ed. by W. Kalow, vol. 137, Porgamon Press, Inc., New York, 1992b.
42. KALOW, W.: Pharmacogenetics: its biologic roots and the medical challenge. Clin. Pharmacol. Ther. 54: 235-241, 1993.
43. KALOW, W., AND BERTILSSON, L.: Interethnic factors affecting drug response. Adv. Drug. Res. 25: l-59, 1994,
44. KALOW, W., AND GRANT, D. M.: Pharmacogenetics. In The Metabolic and Molecular Bases of Inherited Disease, ed. by C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, pp. 293-326, McGraw-Hill, Inc., New York, 1995.
45. KIMURA, M : Evolutionary rule at the molecular level. Nature (Lond.) 217: 624-626, 1968.
46. KWON-CHUNG, K. J., AND BENNETT, J. E.: Medical Mycology. Lea & Febiger, Philadelphia, 1992.
47. LANDS, A. M., NASH, V. L., DERTINGER, B. L., GRANGER, H. R., MCCARTHY, H. M.: The pharmacology of compounds structurally related to hydroxythyramine. J. Pharmacol. 92: 369-380, 1948.
48. LANGMAN, R. E.: The Immune System: Evolutionary Principles Guide Our Understanding of this Complex Biological Defense. Academic Press, San Diego, 1989.
49. LECLERC, J. E., LI, B., PAYNE, W. L., AND CEBULA, T. A.: High mutation frequencies among escherichia coli and salmonella pathogens. Science (Wash. DC) 274: 1208-1211, 1996.
50. LEVIN, B. R.: Conditions for the evolution of multiple antibiotic resistance plasmids: a theoretical and experimental excursion. In Population Genetics of Bacteria, ed. by S. Baumberg, J. P. W. Young, E. M. H. Wellington, and J. R. Saunders, pp. 175-192, Cambridge University Press, Cambridge, UK, 1995.
51. LEVY, S. B., AND NOVICK, R. P.: Antibiotic Resistance Genes: Ecology, Transfer, and Expression. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1986.
52. LILLEHOJ, E. B.: Aflatoxin: genetic mobilization agent. In Handbook of Applied Mycology: Mycotoxins in Ecological Systems, ed. by D. Bhatnagar, E. B. Lillehoj, and D. K. Arora, pp. 1-22, Marcel Dekker, Inc., New York, 1992.
53. LINDAHL, A., SANDSTROM, R., UMGELL, A. L., ABRAHAMSSON, B., KNUTSON, T. W., KNUTSON, L., AND LENNERNAS, H.: Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin. Pharmacol. Ther. 60: 493-503, 1996.
54. LLERENA, A., EDMAN, G., COBALEDA, J., BENITEZ, J., SCHALLING, D., AND BERTILSSON, L.: Relationship between personality and debrisoquine hydroxylation capacity: suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta. Psychiatr. Scand. 87: 23-28, 1993.
55. LOU, Y. C., YING, L., BEHTILSSON, L., AND SJOQVIST, F.: Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 2: 852-853, 1987.
56. LOWN, K. S., KOLARS, J. C., THUMMEL, K. E., BARNETT, J. L., KUNZE, K. L., WRIGHTON, S. A., AND WATKINS, P. B.: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug. Metab. Dispos. 22: 947-955, 1994.
57. LUZZATTO, L., AND MEHTA, A.: Glucose 6-phosphate dehydrogenase deficiency. In The Metabolic and Molecular Bases of Inherited Disease, ed. by C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, pp. 3367-3398, McGraw-Hill, Inc., New York, 1995.
58. MAREZ, D., LEGRAND, M., SABBAGH, N., GUIDICE, J. M. L., SPIRE, C., LAFITTE J. J., MEYER, U. A., AND BROLEY, F.: Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7: 293-202, 1997.
59. MASIMIREMBWA, C. M.: Pharmacogenetics of Drug Metabolising Enzymes in a Black African Population, Kongl Carolinska Medico Chirurgiska Instituts, Stockholm, 1995.
60. MASIMIREMBWA, C. M., JOHANSSON, I., HASLER, J. A., AND INGELMAN-SUNDBERG, M.: Genetic polymorphism of cytochrome P450 2D6 in a Zimbabwean population. Pharmacogenetics 3: 275-280, 1993.
61. May, D. G.: Genetic differences in drug disposition J. Clin. Pharmacol. 34: 881-897, 1994.
62. MEYER, U. A., SKODA, R. C., ZANGER, U. M., HEIM, M., AND BROLY, F.: The genetic polymorphism of debrisoquine/sparteine metabolism: molecular mechanisms. In Pharmacogenetics of Drug Metabolism International Encyclopedia of Pharmacology & Therapeutics Series), ed. by W. Kalow, vol. 137, pp. 609-623, Perganion Press, Inc., New York, 1992.
63. MIDHA, K. K., AND BLEME, H. H.: Bio-International. Bioavailability, Bioequivalence and Pharmacokinetics, Medpharm Scientific Publishers, Stuttgart. 1993.
64. MORRELL, C. A., AND CHAPMAN, C. W.: On the determination of the toxicity of Neoarsphenamine: part II - the determination of the characteristic curve for rats. J. Pharmacol, 48: 391-409, 1933.
65. NEBERT, D. W.: Genetic differences in the induction of monooxygenase activities by polycyclic aromatic compounds. Pharmacol. Ther. 8: 395-417, 1979.
66. OKEY, A. B.: Enzyme induction in the cytochrome P-450 system. In Pharmacogenetics of Drug Metabolism (International Encyclopedia of Pharmacology & Therapeutics Series), ed. by W. Kalow, vol, 137. pp. 549-608, Pergamon Press, New York, 1992.
67. PACIFICI, G. M., AND ARACCHIA, G. N.: Advances in Drug Metabolism in Man. European Commission, Luxembourg. 1995.
68. PRICE EVANS, D. A.: Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics, Cambridge University Press, Cambridge, UK. 1993.
69. PROPPING, P., AND NOTHEN, M. M.: Genetic variation of CNS receptors: a new perspective fur pharmacogenetics. Pharmacogenetics 5: 318-325, 1995.
70. ROUSH, R. T., AND MCKENZIE, J. A.: Ecological genetics of inserticide and acaricide resistance. In Annual Review of Entomology, ed. by T. E. Mittler, F. J. Ratlovsky, and V. H. Resh, vol. 32, pp. 361-380. Annual Reviews. Inc., Palo Alto, CA, 1987.
71. ROUSH, R. T., AND TAHASHNIK, B. E.: Pesticide Resistance in Arthropods, Chapman and Hall, New York, 1990.
72. ROUSH, T. T., AND DALY, J. C.: The role of population genetics in resistance research and management. In Pesticide Resistance in Arthropods, ed. by R. T. Roush and B. E. Tabashnik, pp. 97-152, Chapman and Hall, New York, 1990.
73. RUSSELL, A. D., AND CHOPRA, I.: Understanding Antibacterial Action and Resistance, Ellis Horwood, New York, 1990.
74. SCHULTZ, P. G., AND LERNER, R. A.: From molecular diversity to catalysis: lessons from the immune system. Science (Wash. DC) 289: 1835-1442, 1995.
75. SOMMERS, D. K., MONCRIEFF, J., AND AVENANT, J.: Non-correlations between debrisoquine and metoprolol polymorphism in the Venda. Hum. Toxicol. 8: 365-368, 1989.
76. STEINER, E., BERTILSSON, L., SAWE, J., BERTLING, L. AND SJOQVIST, F.: Polymorphic debrisoquine hydroxylation in 757 Swedish .subjects. Clin. Pharmacol, Ther. 44: 431-435, 1988.
77. STORMER, F. C.: Ochratoxin A: a niycotoxin of concern. In Handbook of Applied Mycology: Mycotoxins in Ecological Systems, ed. by D. Bhatnagar, E. B. Lillehoj,and D. K. Arora, vol. 5, pp. 403-432, Marcel Dekker, Inc., New York, 1992.
78. TREVAN, J. W.: The error of determination of toxicity. Proc, R. Soc. Lond. B Boil. Sci. 101: 483-514. 1927.
79. TYNDALE, R., SUNAHARA, R., INABA, T., KALOW, W., GONZALEZ, F., AND NIZNIK, H.: Neuronal cytochrome P450IID1 (debrisoquine/sparteine type): potent inhibition of activity by cocaine and nucleotide sequcnce identity to human hepatic P450 gene CYP2D6. Mol, Pharmacol. 40: 63-68, 1991.
80. VERNIER, P., CARDINAUD, B., VALDEAIRE, O., PHILIPPE, H., AND VINCENT, J. D.: An evolutionary view of drug-receptor interaction: the bioamine receptor family. Trends Pharniacol. Sci. 16: 375-381, 1995.
81. VESELL, E. S.: Pharmacogenetic perspectives gained from twin and family studies. In pharmacugenetics of Drug Metabolism (lnternational Encylopedia of Pharmacology & Therapeutics Series), ed. by W. Kalow, vol. 137, pp. 843-863. Pergamon Press, New York, 1992.
82. VESELL, E. S., AND PAGE, J. G.: Genetic control of drug levels in man: antipyrine. Science (Wash. DC) 161: 72-73, 1968.
83. VIDAL, S. M., MALO, D., VOGAN, K., SKAMENE, E., AND GROS, P.: Natural resistance to inflection with intracellular parasites: isolation of a candidate for Beg. Cell 73: 469-485, 1993.
84. WACHER, V. J., SALPHATI, L., AND BENET, L. Z.: Active secretion and enterocytic drug metabolism barriers to drug absorption Adv. Drug Delivery Rev. 20: 99-112, 1996.
85. WILKINSON, G. R.: Cytochrome P4503A (CYP3A) metabolism: prediction in in vivo activity in humans. J. Pharmacokin. Biopharm. 24: 475-490, 1996.
86. WlLLIAMS, G. C.: Adaptation and Natural Selection: A Critique of Some Current Evolutionary Thought, Princeton University Press, Princeton, 1974.
87. WORLD HEALTH ORGANIZATION: Mycotoxins, World Health Organization, Geneva, 1979.
88. ZIEGLER, D. M.: The 1990 Bernard B, Brodie Award Lecture: unique properties of the enzymes of detoxication. Drug Metab. Dispos. 19: 847-852, 1991.